CT832 : A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Treatment<br/>TrialTypeTreatment
Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Treatment | Bowel (colorectum),Breast,Head and neck,Lung,Skin,Urinary systemBladder,Breast,Colorectum,Kidney,Melanoma (Skin),Non-Small Cell Lung Cancer,Renal cell carcinoma,

Trial Overview Read MoreRead more

This phase I trial is evaluating a new drug (CPI-444) alone and in combination with atezolizumab in patients with advanced cancers.
 

This trial is treating multiple types of cancer including Non Small Cell Lung Cancer, Melanoma, Renal Cell Cancer, Kidney Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Commercial Sponsor

Corvus Pharmaceuticals, Inc

Summary

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Recruiting Hospitals Read MoreRead more

Cabrini Education and Research Precinct
Malvern
Dr Emma Baker
ebaker@cabrini.com.au
(03) 9508 3493

Monash Medical Centre, Medical Oncology
Clayton
Ms Cheryl-Ann Hawkins
cherylann.hawkins@monashhealth.org
03 8572 2429

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140